Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : US Oncology(USON) -- Ignore unavailable to you. Want to Upgrade?

To: Ram Seetharaman who wrote (73)	10/10/2000 8:41:44 AM
From: Ram Seetharaman	Read Replies (1) \| Respond to of 75

Tuesday October 10, 7:31 am Eastern Time Press Release SOURCE: US Oncology, Inc. USON Announces PET Financing Arrangements HOUSTON, Oct. 10 /PRNewswire/ -- US Oncology, Inc. (Nasdaq: USON - news) announced today the completion of the first round of lease financing for its PET initiative. FINOVA Capital Corporation has been selected to provide the initial $10.5 million investment in USON's PET scanning product line. The investment will be in the form of an operating lease facility. PET (Positron Emission Tomography) technology represents the latest diagnostic development to assist oncologists in the early detection and evaluation of cancerous tissue growth, more accurately and earlier than MRI or CT scans. USON plans an accelerated rollout to over 25 markets in which it operates, establishing itself as the leader in integrating this breakthrough diagnostic technology into the treatment planning process on a national level. ``FINOVA is pleased to provide the first round of financing for USON's PET development,'' said Randy Abrahams, Senior V.P. of FINOVA's Healthcare Finance division. ``USON's technology and growth initiatives clearly demonstrate a business strategy in which FINOVA is proud to participate.'' Dr. Landis Griffeth, a USON network physician in Dallas, Texas, concluded, ``In order to make the most appropriate and cost-effect treatment decisions, oncologists need optimal information regarding the activity of the disease, its extent, as well as its response to treatment. PET's unique capabilities in this arena are giving it an indispensable role in cancer care. Our intent is to make this technology broadly available across our network and to provide the highest quality control to ensure physicians can be confident in the information they receive from PET.'' US Oncology represents the most extensive information platform for understanding cancer and the largest enterprise focused solely on this disease. The FINOVA Group Inc. (NYSE: FNV - news), through its principal operating subsidiary, FINOVA Capital Corporation, is one of the nation's leading financial services companies, focused on providing a broad range of capital solutions primarily to midsize business. FINOVA is headquartered in Scottsdale, Ariz. with business development offices throughout the U.S. and in London, U.K., and Toronto, Canada. For more information, visit the company's website at finova.com. This press release contains forward-looking statements, including statements that include the words ``believes,'' ``expects,'' ``anticipates,'' ``intends'' or similar expressions and statements regarding our prospects. All statements other than statements of fact included in this press release are forward-looking statements. Although the Company believes that the expectations reflected in such statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Matters that could impact future results and financial conditions include reimbursement for healthcare services, particularly reimbursement for chemotherapy agents, integration of formerly separate operations in connection with the AOR-PRN merger, government regulation and the operations of the Company's affiliated physician groups. Please refer to the Company's 1999 Annual Report and Form 10-Q's for the first and second quarters of 2000 for factors that could cause actual results to differ materially from the Company's expectations. SOURCE: US Oncology, Inc.